Wall Street brokerages forecast that Retrophin, Inc. (NASDAQ:RTRX) will post $40.82 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Retrophin’s earnings, with estimates ranging from $39.14 million to $42.50 million. Retrophin posted sales of $33.95 million in the same quarter last year, which would indicate a positive year over year growth rate of 20.2%. The company is scheduled to report its next earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Retrophin will report full year sales of $40.82 million for the current year, with estimates ranging from $152.69 million to $154.80 million. For the next year, analysts expect that the firm will report sales of $184.40 million per share, with estimates ranging from $184.19 million to $184.60 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Retrophin.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). The business had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.07 EPS.

A number of equities analysts recently issued reports on the company. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a report on Friday, August 4th. BidaskClub raised Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $32.33.

Retrophin (NASDAQ RTRX) traded up 1.50% during trading on Wednesday, reaching $23.04. The company had a trading volume of 173,529 shares. The firm has a 50-day moving average of $22.97 and a 200-day moving average of $19.66. The stock’s market capitalization is $884.39 million. Retrophin has a 1-year low of $15.55 and a 1-year high of $25.11.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/retrophin-inc-rtrx-expected-to-announce-quarterly-sales-of-40-82-million/1583628.html.

In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the sale, the chief operating officer now owns 13,622 shares of the company’s stock, valued at approximately $306,495. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.41% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC boosted its holdings in Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 146 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Retrophin by 1.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 290 shares in the last quarter. Legal & General Group Plc boosted its holdings in Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 355 shares in the last quarter. AJO LP boosted its holdings in Retrophin by 1.9% in the 2nd quarter. AJO LP now owns 59,681 shares of the biopharmaceutical company’s stock valued at $1,157,000 after purchasing an additional 1,094 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its holdings in Retrophin by 3.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,471 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 1,200 shares in the last quarter.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.